Halozyme Therapeutics Inc (HALO)

[maumar]

Roche earnings call transcript from SA (page 5):

"Perceptin, we have good sub queue conversion in the markets that were launched. In fact, the MabThera sub queue conversion is near in the Herceptin sub queue or conversion now in the European countries where it's launched. But we have countries that are well over 50%. On average, we have around half of the business in the markets where we're launched with sub queue formulation and Perjeta as I said further increasing."

http://seekingalpha.com/article/4041770-roche-holdings-rhhby-ceo-severin-schwan-q4-2016-results-earnings-call-transcript?page=20